Danish drugmaker Novo Nordisk said several hundred counterfeit units of its diabetes drug Ozempic were being distributed in ...

BMO Capital downgraded Novo Nordisk (NVO) to Market Perform from Outperform with a price target of $64, down from $105. The company’s obesity ...

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the superior commercial and clinical portfolios of the Indianapolis company ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by China-based The United Laboratories International Holdings Limited.

Novo Nordisk has promoted Rishang Deoras to Global Director - Diabetes Commercial Unit.Deoras shared the news in a LinkedIn ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire ...

The U.S. Food and Drug Administration is warning people of counterfeit versions of a popular weight loss drug are circulating ...

Novo Nordisk, the Danish pharmaceutical giant behind obesity drug, Wegovy, has engaged Slingshot to develop and manage its ...

Growth is driven by the rising prevalence of diabetes among the elderly, necessitating efficient insulin delivery solutions ...

Novo Nordisk (NYSE:NVO) has emerged as the most well-held European stock among Global, International, and European long-only... Investing.com – Denmark stocks were higher after the close on ...